Hyperglycemic myocardial damage is mediated by proinflammatory cytokine: Macrophage migration inhibitory factor

PLoS ONE

Volumn 6, Issue 1, 2011, Pages

  Yu, Xi Yong ^a   Chen, Hong Mei ^a   Liang, Jia Liang ^a   Lin, Qiu Xiong ^a   Tan, Hong Hong ^a   Fu, Yong Heng ^a   Liu, Xiao Ying ^a   Shan, Zhi Xin ^a   Li, Xiao Hong ^a   Yang, Hua Zhang ^a   Yang, Min ^a   Li, Yangxin ^b   Lin, Shu Guang ^a  

^a GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CHEMOKINE RECEPTOR CXCR4; G PROTEIN COUPLED RECEPTOR KINASE 2; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; MACROPHAGE MIGRATION INHIBITION FACTOR; SMALL INTERFERING RNA; ADRBK1 PROTEIN, HUMAN; CYTOKINE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLINICAL OBSERVATION; CONTROLLED STUDY; DIABETIC CARDIOMYOPATHY; DIASTOLE; DOPPLER ECHOCARDIOGRAPHY; FEMALE; GLUCOSE BLOOD LEVEL; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE INJURY; HUMAN; HYPERGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; MAJOR CLINICAL STUDY; MALE; MYOBLAST; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOGENESIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; ANIMAL; CASE CONTROL STUDY; HEART DISEASE; IMMUNOLOGY; MIDDLE AGED;

RATTUS;

ADULT; ANIMALS; CASE-CONTROL STUDIES; CYTOKINES; DIABETES MELLITUS, TYPE 2; DIABETIC CARDIOMYOPATHIES; G-PROTEIN-COUPLED RECEPTOR KINASE 2; HEART DISEASES; HUMANS; HYPERGLYCEMIA; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MALE; MIDDLE AGED; RATS;

EID: 79551541593     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0016239     Document Type: Article

References (32)

1. Boyer JK, Thanigaraj S, Schechtman KB, Pe'rez JE (2004) Prevalence of ventricular diastolic dysfunction in asymptomatic, normotensive patients with diabetes mellitus. Am J Cardiol 93: 870-875.
2. Suys BE, Katier N, Rooman RP, Matthys D, Op De Beeck L, et al. (2004) Female children and adolescents with type 1 diabetes have more pronounced early echocardiographic signs of diabetic cardiomyopathy. Diabetes Care 27: 1947-53.
3. Poirier P, Bogaty P, Garneau C, Marois L, Dumesnil JG (2001) Diastolic dysfunction in normotensive men with well-controlled type 2 diabetes: importance of maneuvers in echocardiographic screening for preclinical diabetic cardiomyopathy. Diabetes Care 24: 5-10.
4. Grandi AM, Piantanida E, Franzetti I, Bernasconi M, Maresca A, et al. (2006) Effect of glycemic control on left ventricular diastolic function in type 1 diabetes mellitus. Am J Cardiol 97: 71-6.
5. Bacha F, Gungor N, Lee S, Arslanian SA (2009) In vivo insulin sensitivity and secretion in obese youth: what are the differences between normal glucose tolerance, impaired glucose tolerance, and type 2 diabetes? Diabetes Care 32: 100-5.
6. O'Keefe JH, Bell DS (2007) Postprandial hyperglycemia/hyperlipidemia (postprandial dysmetabolism) is a cardiovascular risk factor. Am J Cardiol 100: 899-904.
7. Herder C, Kolb H, Koenig W, Haastert B, Müller-Scholze S, et al. (2006) Association of systemic concentrations of macrophage migration inhibitory factor with impaired glucose tolerance and type 2 diabetes: results from the Cooperative Health Research in the Region of Augsburg, Survey 4 (KORA S4). Diabetes Care 29: 368-71.
8. Yu XY, Lin SG, Huang XR, Bacher M, Leng L, et al. (2007) Macrophage migration inhibitory factor induces MMP-9 expression in macrophages via the MEK-ERK MAP kinase pathway. J Interferon Cytokine Res 27: 103-9.
9. Willis MS, Carlson DL, Dimaio JM, White MD, White DJ, et al. (2005) Macrophage migration inhibitory factor mediates late cardiac dysfunction after burn injury. Am J Physiol Heart Circ Physiol 288: H795-804.
10. Garner LB, Willis MS, Carlson DL, DiMaio JM, White MD, et al. (2003) Macrophage migration inhibitory factor is a cardiac-derived myocardial depressant factor. Am J Physiol Heart Circ Physiol 285: H2500-9.1.
11. Liang JL, Xiao DZ, Liu XY, Lin QX, Shan ZX, et al. (2010) High glucose induces apoptosis in AC16 human cardiomyocytes via macrophage migration inhibitory factor and c-Jun N-terminal kinase. Clin Exp Pharmacol Physiol 37: 969-973.
12. Hansen JL, Theilade J, Aplin M, Sheikh SP (2006) Role of G-protein-coupled receptor kinase 2 in the heart--do regulatory mechanisms open novel therapeutic perspectives? Trends Cardiovasc Med 16: 169-77.
13. Bartels ED, Bang CA, Nielsen LB (2009) Early atherosclerosis and vascular inflammation in mice with diet-induced type 2 diabetes. Eur J Clin Invest 39: 190-9.
14. Yabunaka N, Nishihira J, Mizue Y, Tsuji M, Kumagai M, et al. (2000) Elevated serum content of macrophage migration inhibitory factor in patients with type 2 diabetes. Diabetes Care 23: 256-8.
15. Bernhagen J, Krohn R, Lue H, Gregory JL, Zernecke A, et al. (2007) MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat Med 13(5): 587-96.
16. Noels H, Bernhagen J, Weber C (2009) Macrophage migration inhibitory factor: a noncanonical chemokine important in atherosclerosis. Trends Cardiovasc Med 19: 76-86.
17. Verschuren L, Kooistra T, Bernhagen J, Voshol PJ, Ouwens DM, et al. (2009) MIF deficiency reduces chronic inflammation in white adipose tissue and impairs the development of insulin resistance, glucose intolerance, and associated atherosclerotic disease. Circ Res 105: 99-107.
18. Dandona P, Aljada A, Ghanim H, Mohanty P, Tripathy C, et al. (2004) Increased plasma concentration of macrophage migration inhibitory factor (MIF) and MIF mRNA in mononuclear cells in the obese and the suppressive action of metformin. J Clin Endocrinol Metab 89: 5043-7.
19. Morand EF, Leech M, Bernhagen J (2006) MIF: a new cytokine link between rheumatoid arthritis and atherosclerosis. Nat Rev Drug Discov 5(5): 399-410.
20. Burger-Kentischer A, Goebel H, Seiler R, Fraedrich G, Schaefer HE, et al. (2002) Expression of macrophage migration inhibitory factor in different stages of human atherosclerosis. Circulation 105: 1561-6.
21. Pan JH, Sukhova GK, Yang JT, Wang B, Xie T, et al. (2004) Macrophage migration inhibitory factor deficiency impairs atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation 109(25): 3149-53.
22. Schober A, Bernhagen J, Thiele M, Zeiffer U, Knarren S, et al. (2004) Stabilization of atherosclerotic plaques by blockade of macrophage migration inhibitory factor after vascular injury in apolipoprotein E-deficient mice. Circulation 109(3): 380-5.
23. Penela P, Ribas C, Mayor F, Jr. (2003) Mechanisms of regulation of the expression and function of G protein-coupled receptor kinases. Cell Signal 15(11): 973-81.
24. An D, Rodrigues B (2006) Role of changes in cardiac metabolism in development of diabetic cardiomyopathy. Am J Physiol Heart Circ Physiol 291: H1489-506.
25. Tevaearai HT, Koch WJ (2004) Molecular restoration of beta-adrenergic receptor signaling improves contractile function of failing hearts. Trends Cardiovasc Med 14(6): 252-6.
26. Park TS, Hu Y, Noh HL, Drosatos K, Okajima K, et al. (2008) Ceramide is a cardiotoxin in lipotoxic cardiomyopathy. J Lipid Res 49: 2101-12.
27. Mandrup-Poulsen T (2003) Apoptotic signal transduction pathways in diabetes. Biochem Pharmacol 66: 1433-40.
28. Penela P, Murga C, Ribas C, Tutor AS, Peregrin S, et al. (2006) Mechanisms of regulation of G protein-coupled receptor kinases (GRKs) and cardiovascular disease. Cardiovasc Res 69: 46-56.
29. Takahashi M, Nishihira J, Shimpo M, Mizue Y, Ueno S, et al. (2001) Macrophage migration inhibitory factor as a redox-sensitive cytokine in cardiac myocytes. Cardiovasc Res 52: 438-45.
30. Yu XY, Song YH, Geng YJ, Lin QX, Shan ZX, et al. (2008) Glucose induces apoptosis of cardiomyocytes via microRNA-1 and IGF-1. Biochem Biophys Res Commun 376: 548-552.
31. Dhanantwari P, Nadaraj S, Kenessey A, Chowdhury D, Al-Abed Y, et al. (2008) Macrophage migration inhibitory factor induces cardiomyocyte apoptosis. Biochem Biophys Res Commun 371: 298-303.
32. Tripathy D, Mohanty P, Dhindsa S, Syed T, Ghanim H, et al. (2003) Elevation of free fatty acids induces inflammation and impairs vascular reactivity in healthy subjects. Diabetes 52(12): 2882-7.